It is estimated that there are approximately 6,500 adults living with severe hemophilia A in the U.S. BioMarin expects approximately 2,500 of those adults to be eligible to receive ROCTAVIAN with this initial approval.这个说法A型血友病美国6500
很遗憾uniqure已经把这药卖给了csl,只有里程碑和分段的特许权收入,据说特许权最高分成达到20%。
A型血友病是大得多的适应症,发病率是B型血友病(占比15%)的约6倍。按照$拜玛林制药(BMRN)$ 说法,欧美一共12万病人,一半重症,再一半无Aav免疫。所以是3万适合的现存患者。
It is estimated that there are approximately 6,500 adults living with severe hemophilia A in the U.S. BioMarin expects approximately 2,500 of those adults to be eligible to receive ROCTAVIAN with this initial approval.这个说法A型血友病美国6500
不算少,特别是欧洲更多。但是过两年大概率所有病人都会优先考虑用$CRISPR Therapeutics(CRSP)$和$福泰制药(VRTX)$的crsipr疗法。